Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12442013 | 0.88 | GRM2 (0.41) | GRM2HCRTR1HCRTR2DAOTNIK | |
| SCHEMBL2022893 | 0.88 | GRM2 (0.43) | GRM2HCRTR1HCRTR2DAOTNIK | |
| SCHEMBL2022199 | 0.87 | TNIK (0.36) | HCRTR1HCRTR2DAOTNIK | |
| SCHEMBL2021448 | 0.86 | TNIK (0.36) | GRM2HCRTR1HCRTR2DAOTNIK | |
| SCHEMBL13613663 | 0.84 | GRM2 (0.56) | GRM2HCRTR1HCRTR2 | |
| SCHEMBL13613668 | 0.83 | KMT2A (0.41) | GRM2P2RX7MEN1KMT2A | |
| SCHEMBL13613666 | 0.83 | P2RX7 (0.42) | GRM2P2RX7 | |
| SCHEMBL13613660 | 0.82 | PARP1 (0.48) | MEN1KMT2A | |
| SCHEMBL2022810 | 0.80 | TNIK (0.37) | HCRTR1HCRTR2DAOTNIKMEN1 | |
| SCHEMBL13613675 | 0.80 | CHRM5 (0.42) | GRM2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885P2RX7 93/4885HCRTR1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.